United Therapeutics to develop, sell Arena Pharma's hypertension treatment
United Therapeutics Corp on Thursday signed a deal potentially worth up to $1.2 billion for the rights to develop and sell Arena Pharmaceuticals Inc's pulmonary arterial hypertension treatment . The two companies said the deal for Arena's late-stage experimental treatment, ralinepag, includes milestone payments of up to $400 million based on certain regulatory events in addition to an upfront payment of $800 million.
from Biotech News
0 Comments